Wednesday, December 3, 2025

Is CME Group Stock Outperforming the Nasdaq?

CME Group Inc. (CME) is a major force in global finance, a Chicago-based titan that has grown into the world’s preeminent arena for derivatives trading. What began as separate, historic exchanges has evolved into a unified powerhouse, bringing together the Chicago Mercantile Exchange, Chicago Board of Trade, NYMEX, and COMEX under one formidable umbrella.

From interest rates and equities to currencies, energy, agriculture, and precious metals, CME Group serves as the silent engine behind markets that never sleep. Its flagship electronic platform, CME Globex, delivers instant access, sharp price discovery, and industrial-grade risk management to participants across continents, ensuring that capital flows remain steady even when volatility strikes. Its market capitalization stands at around $101.3 billion.

Companies worth $10 billion or more typically earn the “large-cap” badge, and CME clears that bar with ease. That size reflects more than just market value; it reflects decades of building influence, trust, and irreplaceable infrastructure in the global derivatives ecosystem. CME did not stumble into large-cap territory but earned it by becoming the backbone of risk management across interest rates, equity indexes, foreign currencies, and commodities. With exclusive rights to list and clear S&P futures and an unmatched product breadth, CME’s rise into large-cap prestige was driven by necessity as much as success – the global financial system simply runs smoother with CME at the center.

That strength was on display earlier this year when CME stock touched a fresh 52-week high of $290.79 on June 2. While shares currently sit about 3.1% below that peak, the stock’s short-term performance still shows resilience. Over the past three months, CME gained 3.4%, not quite enough to beat the Nasdaq Composite’s ($NASX) 7.8% uptick, but steady enough to show investors are not backing away.

www.barchart.com
www.barchart.com

The longer-term picture adds even more clarity. CME stock has climbed 20.9% on a year-to-date (YTD) basis and surged 19.8% over the past 52 weeks. That performance slightly edges out the NASX’s YTD gains of 20.2%, though it narrowly trails the broader index’s 21.1% rise over the past year. CME may not be sprinting, but it is keeping pace and occasionally outshining the market’s fastest runners.

Source link

Hot this week

Salesforce’s Stock Is Historically Cheap as AI Risk Takes a Toll

(Bloomberg) -- Salesforce Inc. shares have...

Desk-bound employees increasingly prone to frozen shoulder, say experts

Frozen shoulder -- medically known as adhesive capsulitis --...

L’Oréal Will Start Work on Potential Armani Deal ‘Very Soon’, Says CFO

French cosmetics group L’Oréal will “definitely” look at...

Alphabet to Enforce Australia’s Under-16 Social Media Ban on YouTube

This article first appeared on GuruFocus....

Givaudan Acquires US Perfume Manufacturer Belle Aire Creations

Swiss fragrance maker Givaudan has acquired US fragrance...

Topics

Desk-bound employees increasingly prone to frozen shoulder, say experts

Frozen shoulder -- medically known as adhesive capsulitis --...

L’Oréal Will Start Work on Potential Armani Deal ‘Very Soon’, Says CFO

French cosmetics group L’Oréal will “definitely” look at...

Givaudan Acquires US Perfume Manufacturer Belle Aire Creations

Swiss fragrance maker Givaudan has acquired US fragrance...

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Both can help drive excellent returns for patient, disciplined...

The UK Watchdog Doubles Reporting Burden, Including FX And CFD Brokers, Starting 2027

The UK's Financial Conduct Authority (FCA) rolled out a major revamp...

Related Articles

Popular Categories

spot_img